ddrg/super_eurlex huggingface dataset:
Non-opposition to a notified concentration

(Case M.10197 — CSS/Visana/Zur Rose/medi24/WELL JV)

(Text with EEA relevance)

(2021/C 184/03)

On 6 May 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No. 139/2004 (1). The full text of the decision is available only in German language and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10197. EUR-Lex is the online access to the European law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.10228 — Advent/Mondial Relay)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 170/10)

1. On 30 April 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Advent International Corporation (‘Advent’, USA), — Mondial Relay SAS (‘Mondial Relay’, France). Advent, indirectly through InPost SA, acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Mondial Relay. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for Advent: a private equity investment fund focused on the acquisition of equity stakes and the management of interests in various sectors, including business and financial services; industrial goods and services; retail operations, branded consumer goods, and leisure services; media, telecommunications, and information technology; and healthcare services and pharmaceuticals. Through its controlled portfolio companies, Hermes UK, Hermes Germany and InPost SA, Advent is active in ‘Pick-Up & Drop-Off’ (‘PUDO’) network services and small package delivery services in the UK, Germany, Poland and Italy, respectively, and to a minor extent in cross-border deliveries, — for Mondial Relay: a company active in the provision of PUDO network services and small package delivery services in France, Belgium, Luxembourg, the Netherlands, Portugal and Spain. To a minor extent, Mondial Relay is also active in cross-border deliveries.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10228 — Advent/Mondial Relay Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10170 — Shell/NXK)

(Text with EEA relevance)

(2021/C 192/01)

On 11 May 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10170. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10275 — SMFL/Yanmar/Yanmar Credit)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 205/05)

1. On 19 May 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Sumitomo Mitsui Finance and Leasing Co., Ltd. (‘SMFL’, Japan), jointly controlled by Sumitomo Mitsui Financial Group, Inc. (Japan) and Sumitomo Corporation (Japan); — Yanmar Holdings Co., Ltd. (‘Yanmar’, Japan); — Yanmar Credit Service Co., Ltd. (‘Yanmar Credit’, Japan), currently controlled by Yanmar. SMFL and Yanmar acquire within the meaning of Article 3(1)(b) and Article 3(4) of the Merger Regulation joint control of Yanmar Credit. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — SMFL offers a variety of financing services to its customers. Its core business is the provision of leasing services (financial leasing and operational leasing), rental services and installment sales services; — Yanmar is active in the sale of engines used in a wide range of applications, energy systems and generators as well as agricultural machinery, compact construction equipment, components and boats; — Yanmar Credit offers financing services in Japan.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10275 - SMFL/Yanmar/Yanmar Credit Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10281 — Astorg/Cobepa/Corsearch)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 201/10)

1. On 17 May 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Astorg Asset Management S.a.r.l. (‘Astorg’, Luxembourg) — Cobepa SA (‘Cobepa’, Belgium) — Corsearch US Holdings, Inc. (‘Corsearch’, USA). Astorg and Cobepa acquire within the meaning of Articles 3(1)(b) and 3(4) of the Merger Regulation joint control of Corsearch. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for Astorg: private equity firm that seeks to partner with entrepreneurial management teams to acquire global companies and create value through the provision of strategic guidance, experienced governance and adequate capital, — for Cobepa: privately held investment company centred on growth capital investments and buy-out acquisitions and mainly seeking investment opportunities in Europe and North America, — for Corsearch: data, analytics, and services that support brands to market their assets and reduce commercial risks as well trademark clearances support and brand protection.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10281 – Astorg/Cobepa/Corsearch Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email:COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Prior notification of a concentration

(Case M.10165 — Astrazeneca/Alexion Pharmaceuticals)

(Text with EEA relevance)

(2021/C 215/09)

AstraZeneca acquires, within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of the whole of Alexion. The concentration is accomplished by way of purchase of shares.

On 31 May 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 )

for Alexion: US biopharmaceutical company focusing on rare and ultra-rare diseases for which there is high unmet medical need.

for AstraZeneca: global pharmaceutical company engaged in the development and commercialisation of medicines in following core therapy areas: (i) oncology; (ii) cardiovascular, renal & metabolism; and (iii) respiratory & immunology;

The business activities of the undertakings concerned are:

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10165 — Astrazeneca/Alexion Pharmaceuticals

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:
Official Journal of the European Union

Prior notification of a concentration

(Case M.10272 — Utmost/Quilter International)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 210/05)

1. On 21 May 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Utmost Group Limited (‘Utmost’, United Kingdom), controlled by Oaktree Capital Group Holdings GP, LLC (‘Oaktree’, United Kingdom) and Brookfield Asset Management Inc. (‘Brookfield’, USA), — Quilter International Holdings and Quilter International Ireland Designated Activity Company (together, ‘Quilter International’, Ireland). Utmost acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Quilter International. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — Utmost is a specialist life assurance group. Through its group companies, Utmost provides (i) international life assurance to high-net-worth and ultra-high-net-worth individuals, (ii) savings and employee benefit services, and (iii) life insurance consolidation services in the UK. Utmost is controlled by Oaktree and Brookfield, which both provide asset management services worldwide. — Quilter International provides cross-border investment life assurance solutions in the UK, Europe, the Middle East, Asia and Latin America.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10272 – Utmost/Quilter International Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10303 — Astorg/Bridgepoint/Fenergo)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 226/08)

1. On 7 June 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Astorg VII SCSp (represented by Astorg Asset Management S. à r. l.) and the other affiliates of the Astorg group (‘Astorg’, Luxembourg), — Bridgepoint Europe VI Fund (‘Bridgepoint’, United Kingdom), — Fenergo Group Limited (‘Fenergo’, Ireland). Astorg and Bridgepoint acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Fenergo. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — Astorg is a private equity group, that works with entrepreneurial management teams to acquire companies and offer strategic guidance, governance and capital, — Bridgepoint is an international alternative asset management group, investing in established Europe-focused middle market businesses in a broad range of sectors, — Fenergo is a provider of software solutions aimed at helping banks and financial institutions operate effectively.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10303 — Astorg/Bridgepoint/Fenergo Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10242 — Melitta/Hubert Burda Media/Roast Market)

(Text with EEA relevance)

(2021/C 219/04)

On 21 May 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No. 139/2004 (1). The full text of the decision is available only in German language and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10242. EUR-Lex is the online access to the European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10158 — IHS Markit/CME Group/JV)

(Text with EEA relevance)

(2021/C 244/11)

1. On 15 June 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — IHS Markit Ltd, (‘IHSM’, United Kingdom) — CME Group (‘CME’, United States of America) — Parthenon Ltd (‘Parthenon’, Bermuda) IHSM and CME acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Parthenon, a newly created joint venture company. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for IHSM: international provider of information, analytics, expertise, and solutions to major industries, financial markets, and governments globally. IHSM provides pricing and reference data, financial indices, security identifiers, valuation and trading services, and data feeds/data management solutions, — for CME: US based global risk management firm. CME owns and operates several exchanges (Chicago Mercantile Exchange, Chicago Board of Trade (CBOT), New York Mercantile Exchange (NYMEX) and the Commodity Exchange (COMEX)) and provides other trading and clearing services across a range of asset classes, including commodities, equity indices, FX, IRDs and cryptocurrencies, — for Parthenon: trade processing and trade/portfolio optimization services in a number of asset classes, namely IHSM’s OTC derivatives and FX trade processing business (known as MarkitSERV) and CME’s OTC derivatives optimization businesses (Traiana, TriOptima and Reset).

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10158 — IHS Markit/CME Group/JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
Prior notification of a concentration

(Case M.10280 – ABP/Slaney/Linden)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 236/07)

ABP acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Slaney and Linden. The concentration is accomplished by way of purchase of shares.

On 10 June 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 )

for Slaney and Linden: slaughtering of cattle and ovine animals, the processing of their meat and the collection and processing of animal by-products in Ireland and Belgium Slaney and in the UK for Linden.

for ABP: slaughtering of cattle and ovine animals (lamb and sheep), processing of their meat and collection and processing of associated animal by-products,

The business activities of the undertakings concerned are:

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10280 – ABP/Slaney/Linden

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:
Non-opposition to a notified concentration

(Case M.10297 — CDPQ/OTPP/Ohio)

(Text with EEA relevance)

(2021/C 254/02)

On 18 June 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10297. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration

(Case M.10279 — TFS/Mitsui/MAF Colombia)

(Text with EEA relevance)

(2021/C 245/03)

On 18 June 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10279. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.